Fig. 1 · Structure
Documents & Downloads
LH708
L-cystine Crystallization Inhibitor
LH708 is an orally active inhibitor of L-cystine crystallization, demonstrating an EC50 of 59.8 nM. This compound is particularly useful for research on cystinuria, a genetic disorder characterized by the formation of cystine crystals in the kidneys. LH708 provides valuable insights into therapeutic strategies aimed at managing cystine crystal formation and associated renal complications.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Inhibitor |
| CAS Number | 1616757-93-7 |
| Applications | L-cystine Crystallization Inhibitor |
| Formula | C16H36Cl4N6O2S2 |
| Molecular Weight | 550.44 |
| SMILES | CN1CCN(C([C@@H](N)CSSC[C@H](N)C(N2CCN(C)CC2)=O)=O)CC1.Cl.Cl.Cl.Cl |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.